Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
This randomized phase Ib trial studies standard-dose or high-dose erlotinib hydrochloride before surgery in treating patients with head and neck cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Epistemonikos ID: 68eb6b7313bc974be95bcc0106c183e05782f4c6
First added on: May 05, 2024